Vice-President, Scientific Affairs
Melinta Therapeutics
In his current role as Vice-President of Scientific Affairs at Melinta Therapeutics, he directs research and development, education, and publications. His expertise includes infections due to Gram-negative and Gram-positive infections, Clostridium difficile, community-acquired and healthcare-associated pneumonias, mechanisms of bacterial resistance, antimicrobial stewardship, epidemiology, and antimicrobial pharmacokinetics and pharmacodynamics.
Mark’s passion has been to develop and implement programs which advance antimicrobial stewardship to a level of improved patient outcomes and decreased hospital-acquired infections. From his 12 years as the Division Chair for Antimicrobial Stewardship and Research at a 5-hospital system in southern California, Mark has developed an acute understanding on the need to provide optimal antibiotic prescribing and monitoring via a disease state management program and documented over 17,000 interventions on antibiotic prescribing between 1992 and 2000. Mark also participated in microbial resistance research and several clinical trials.
Mark currently holds memberships in the Society of Infectious Diseases Pharmacists (SIDP), Infectious Diseases Society of America (IDSA), Infectious Diseases Association of California (IDAC), Arizona Society of Infectious Diseases (ARIDS), American Society of Microbiology (ASM), and American College of Clinical Pharmacy (ACCP). Mark has served on the committees for antimicrobial stewardship for the California Department of Public Health to help design statewide metrics for stewardship. He served on the SIDP Subcommittees for both Research Grants and Antimicrobial Stewardship Certification. He also served on the Executive Committee for the California Medical Association Foundation’s AWARE Program (antibiotic resistance) from 1998 to 2004. Mark serves on the CLSI Working Group (M39) on antibiogram development (2000-current).